Core Viewpoint - SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. will acquire approximately 54.01% of CliniQuantum Ltd. through a definitive share purchase agreement, enhancing its portfolio in the pharmaceutical and quantum technology sectors [1][3]. Company Overview - SciSparc Ltd. focuses on clinical-stage pharmaceutical developments, particularly in cannabinoid pharmaceuticals, with ongoing drug development programs targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder [7]. - NeuroThera Labs Inc. is dedicated to developing novel therapeutics for central nervous system disorders and other underserved health conditions [8]. Transaction Details - NeuroThera will acquire 56,375 CliniQ Shares, representing approximately 54.01% of CliniQ's issued and outstanding ordinary shares, from the Selling Shareholders [3]. - The consideration for the Purchased Shares includes 56,600,000 common shares of NeuroThera, valued at approximately $9,459,954.20 based on the average trading price over the preceding 20 days [4]. - Selling Shareholders may receive earn-out payments of up to $2,500,000, contingent upon achieving specific milestones, including payments for patent applications and a percentage of fundraising proceeds [5]. Closing Timeline - The closing of the transaction is expected within 30 days after submitting an application for an Israeli tax ruling, anticipated around March 31, 2026, subject to closing conditions [6].